Biogen Shares Rise After JPMorgan Upgrade

JPMorgan upgraded Biogen to Overweight, setting a $300 price target for 2027, implying 33% upside. The bank cited potential catalysts, including felzartamab for kidney transplant complications, Leqembi for Alzheimer's, and litifilimab for lupus. Analyst Chris Schott expects Biogen's earnings growth to accelerate by 2030.

Biogen (BIIB) stock rose 3.8% after JPMorgan upgraded it to Overweight, raising its price target to $300 from $210. The upgrade cited 2027 pipeline catalysts, including felzartamab and litifilimab, and recent Phase 2 data for litifilimab. Biogen's Q3 2026 earnings report, due October 28, may also contribute to investor interest.

Biogen (BIIB) shares rose 3.5% premarket after JPMorgan upgraded it to Overweight with a $300 price target, up from $210. The analyst cited potential catalysts like felzartamab and litifilimab, and noted Biogen's valuation at 14x 2027 earnings. Shares later cooled to $231.37, up 2.5%. Biogen is up 30.2% YTD, hitting a 52-week high.

JPMorgan upgraded Biogen (BIIB) to Overweight, setting a 2027 price target of $300. Analyst Chris Schott cited upcoming clinical catalysts, including Felzartamab and litifilimab, and a positive outlook for Leqembi. The bank expects Biogen's growth to accelerate through 2030, with shares trading at ~14x 2027 EPS.

JPMorgan upgraded Biogen (BIIB) to overweight, raising its price target to $300 from $210, citing upcoming clinical trial data for felzartamab and litifilimab. Analyst Chris Schott expects significant growth opportunities from these drugs, with data releases in 2026 and 2027. Biogen's shares have risen 28% year-to-date.

Biogen (BIIB) shares rose 2.1% premarket after JPMorgan upgraded the stock to overweight, citing a promising pipeline and setting a $300 price target. The company's GF Value™ indicates a modest overvaluation, while its GF Score™ stands at 73 out of 100, reflecting balanced financial health.